IOVA
$10.25
▲ +2.30%09/18 O 10.12 H 10.27 L 9.83 C 10.25 ▲ +2.30%
Vol 22.9M RS 98
Vol 22.9M RS 98
RS rating98
Now vs pivot (%)+238.28%
Tightening (ATR ratio)1.40×
Volume dry-up1.32×
Up/down volume, net0.34
From 52-week high7%
played out
Iovance Biotherapeutics, Inc. Common Stock
IOVA · Biotechnology · $4.6B
Powering up
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
All four are in order, fastest above slowest — every timeframe pointing the same way.
The read
The base has run 3.6 weeks and fell 26% from its ceiling at its deepest. The pivot is $3.03, and the stock closed 238.3% above that pivot. Its relative strength rating is 98.
Peers
Catalyst roadmap
- Earningstentativein 48dQuarterly earningsNov 5, 2026
Flagged by the market sweep
GappedTape · 2026-09-17
+5.4%
GappedTape · 2026-09-15
+7.7%
GappedTape · 2026-09-12
+5.7%
From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means.
In the news
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire Inc. · 1 day ago4 Biotech Stocks to Watch as Potential Takeover TargetsZacks Investment Research · 1 day agoIovance Biotherapeutics to Present at Upcoming ConferencesGlobeNewswire Inc. · 2026-09-04Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsightGlobeNewswire Inc. · 2026-09-03
Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.
Insiders
No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.
X-ray